FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220692866> ?p ?o ?g. }

• W4220692866 endingPage "1224" @default.
• W4220692866 startingPage "1224" @default.
• W4220692866 abstract "Background: There is evidence that vitamin B12 and associated metabolite levels are changed in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH); however, their association has been in dispute. Methods: We included 8397 individuals without previous liver condition or excess alcohol intake from the National Health and Nutrition Examination Survey (NHANES) 1999–2004. NAFLD was diagnosed with Fatty Liver Index (FLI) ≥ 60 or USFLI ≥ 30, and participants with advanced fibrosis risks were identified with elevated non-alcoholic fatty liver disease fibrosis score (NFS), fibrosis 4 index (FIB-4), or aspartate aminotransferase (AST)/platelet ratio index (APRI). Step-wide logistic regression adjusting for confounders was used to detect the association between NAFLD or advanced fibrosis with serum vitamin B12, folate, red blood cell folate (RBC folate), homocysteine (HCY), and methylmalonic acid (MMA). Results: The weighted prevalence of NAFLD was 44.2%. Compared with non-NAFLD participants, patients with NAFLD showed significantly increased RBC folate level and RBC counts, decreased serum vitamin B12 and folate, and similar HCY and MMA levels. NAFLD with advanced fibrosis risk had higher MMA and HCY, reduced serum vitamin B12, and similar serum folate and RBC folate levels than NAFLD with low fibrosis risk. Only RBC folate was independently associated with an increased risk of NAFLD (OR (95% CI): 2.24 (1.58, 3.18)). In all participants, MMA (OR: 1.41 (1.10, 1.80)) and HCY (OR: 2.76 (1.49, 5.11)) were independently associated with increased risk for advanced fibrosis. In participants with NAFLD, this independent association still existed (OR: 1.39 (1.04, 1.85) for MMA and 1.95 (1.09, 3.46) for HCY). In all participants, the area under the receiver operating characteristic curve (ROC AUC) on fibrosis was 0.6829 (0.6828, 0.6831) for MMA and 0.7319 (0.7318, 0.7320) for HCY; in participants with NAFLD, the corresponding ROC AUC was 0.6819 (0.6817, 0.6821) for MMA and 0.6926 (0.6925, 0.6928) for HCY. Conclusion: Among vitamin B12-associated biomarkers, RBC folate was independently associated with elevated NAFLD risk, whereas MMA and HCY were associated with increased risk for advanced fibrosis in the total population and NAFLD participants. Our study highlighted the clinical diagnostic value of vitamin B12 metabolites and the possibility that vitamin B12 metabolism could be a therapeutic target for NASH. Further studies using recent perspective data with biopsy proven NASH could be conducted to validate our results." @default.
• W4220692866 created "2022-04-03" @default.
• W4220692866 creator A5015002294 @default.
• W4220692866 creator A5027475930 @default.
• W4220692866 creator A5046260430 @default.
• W4220692866 creator A5054525661 @default.
• W4220692866 creator A5055387685 @default.
• W4220692866 creator A5065037360 @default.
• W4220692866 creator A5081953591 @default.
• W4220692866 creator A5091910110 @default.
• W4220692866 date "2022-03-14" @default.
• W4220692866 modified "2023-10-16" @default.
• W4220692866 title "The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004" @default.
• W4220692866 cites W1965423912 @default.
• W4220692866 cites W1975701178 @default.
• W4220692866 cites W2018768907 @default.
• W4220692866 cites W2021210310 @default.
• W4220692866 cites W2034639072 @default.
• W4220692866 cites W2060798922 @default.
• W4220692866 cites W2080542886 @default.
• W4220692866 cites W2081324449 @default.
• W4220692866 cites W2093935755 @default.
• W4220692866 cites W2095075233 @default.
• W4220692866 cites W2111946630 @default.
• W4220692866 cites W2112496618 @default.
• W4220692866 cites W2117312367 @default.
• W4220692866 cites W2118655749 @default.
• W4220692866 cites W2126616453 @default.
• W4220692866 cites W2134058536 @default.
• W4220692866 cites W2142690286 @default.
• W4220692866 cites W2153735417 @default.
• W4220692866 cites W2160400039 @default.
• W4220692866 cites W2162382402 @default.
• W4220692866 cites W2163013741 @default.
• W4220692866 cites W2256221996 @default.
• W4220692866 cites W2280248243 @default.
• W4220692866 cites W2559636481 @default.
• W4220692866 cites W2564143363 @default.
• W4220692866 cites W2604148433 @default.
• W4220692866 cites W2701978336 @default.
• W4220692866 cites W2738162532 @default.
• W4220692866 cites W2759997926 @default.
• W4220692866 cites W2903133800 @default.
• W4220692866 cites W2920805195 @default.
• W4220692866 cites W3008564638 @default.
• W4220692866 cites W3011086424 @default.
• W4220692866 cites W3012324149 @default.
• W4220692866 cites W3017024862 @default.
• W4220692866 cites W3024293031 @default.
• W4220692866 cites W3039614361 @default.
• W4220692866 cites W3049751619 @default.
• W4220692866 cites W3083941511 @default.
• W4220692866 cites W3091225481 @default.
• W4220692866 cites W3091471007 @default.
• W4220692866 cites W3118249716 @default.
• W4220692866 cites W3128221353 @default.
• W4220692866 cites W3186787841 @default.
• W4220692866 cites W3201257031 @default.
• W4220692866 cites W4233143493 @default.
• W4220692866 cites W52603844 @default.
• W4220692866 doi "https://doi.org/10.3390/nu14061224" @default.
• W4220692866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35334881" @default.
• W4220692866 hasPublicationYear "2022" @default.
• W4220692866 type Work @default.
• W4220692866 citedByCount "13" @default.
• W4220692866 countsByYear W42206928662022 @default.
• W4220692866 countsByYear W42206928662023 @default.
• W4220692866 crossrefType "journal-article" @default.
• W4220692866 hasAuthorship W4220692866A5015002294 @default.
• W4220692866 hasAuthorship W4220692866A5027475930 @default.
• W4220692866 hasAuthorship W4220692866A5046260430 @default.
• W4220692866 hasAuthorship W4220692866A5054525661 @default.
• W4220692866 hasAuthorship W4220692866A5055387685 @default.
• W4220692866 hasAuthorship W4220692866A5065037360 @default.
• W4220692866 hasAuthorship W4220692866A5081953591 @default.
• W4220692866 hasAuthorship W4220692866A5091910110 @default.
• W4220692866 hasBestOaLocation W42206928661 @default.
• W4220692866 hasConcept C126322002 @default.
• W4220692866 hasConcept C2777090595 @default.
• W4220692866 hasConcept C2778772119 @default.
• W4220692866 hasConcept C2779134260 @default.
• W4220692866 hasConcept C2779478299 @default.
• W4220692866 hasConcept C2779750884 @default.
• W4220692866 hasConcept C2779874844 @default.
• W4220692866 hasConcept C2780221984 @default.
• W4220692866 hasConcept C2780559512 @default.
• W4220692866 hasConcept C2908647359 @default.
• W4220692866 hasConcept C71924100 @default.
• W4220692866 hasConcept C90924648 @default.
• W4220692866 hasConcept C99454951 @default.
• W4220692866 hasConceptScore W4220692866C126322002 @default.
• W4220692866 hasConceptScore W4220692866C2777090595 @default.
• W4220692866 hasConceptScore W4220692866C2778772119 @default.
• W4220692866 hasConceptScore W4220692866C2779134260 @default.
• W4220692866 hasConceptScore W4220692866C2779478299 @default.
• W4220692866 hasConceptScore W4220692866C2779750884 @default.
• W4220692866 hasConceptScore W4220692866C2779874844 @default.
• W4220692866 hasConceptScore W4220692866C2780221984 @default.

• next